Guardant Health said Thursday it is adding Nuvalent in a multi-year collaboration that expands use of its Infinity platform and biopsy portfolio in targeted cancer drug development, trial enrollment and potential companion diagnostics. The deal extends Guardant’s growing role in oncology studies after similar agreements with Pfizer and Merck, with Nuvalent set to use tissue and liquid biopsy tools across parts of its global clinical development program.

Why It Matters To Oncology

• Guardant’s liquid biopsy tests analyze circulating tumor DNA from a blood draw, giving developers a less invasive way to profile tumors than tissue biopsy.

• That could help clinicians and sponsors track molecular evolution and resistance more frequently during development.

• For targeted therapies, tighter integration of testing with enrollment and biomarker selection can improve matching of patients to investigational drugs.

The Financials

• Terms of the multi-year Nuvalent agreement were not disclosed.

• The collaboration covers potential development of companion diagnostics tied to Nuvalent’s investigational kinase-targeted oncology drugs.

• If any therapies are approved, the companies plan to coordinate commercial launches in major global markets.

What They're Saying

• Guardant is positioning Infinity as a platform that gives drug developers deeper molecular detail as tumors evolve and develop resistance.

• Nuvalent will use Guardant’s tissue and liquid biopsy portfolio in selected parts of its global clinical program, though the companies did not identify the specific studies or assets involved.

• The partnership signals continued demand for integrated biomarker, enrollment and regulatory support in precision oncology.

What's Next

• The companies will assess whether Guardant’s assays can be advanced as companion diagnostics for Nuvalent’s current investigational drugs.

• Any companion diagnostic path could later support regulatory filings if those therapies progress successfully.

• Clinicians and drug developers will be watching for which tumor types, biomarkers and trial programs are ultimately included.